Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14279 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Sydni Martinez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Cytomegalovirus Infections, Valganciclovir, Antiviral Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Lung transplant recipients are at high risk for severe cytomegalovirus (CMV) disease. Off‐label use of letermovir (LET) may avert myelotoxicity associated with valganciclovir (VGCV), but data in lung transplantation are limited. This study aims to evaluate the outcomes of LET prophylaxis among lung transplant recipients.
Methods
This retrospective, matched cohort study included lung transplant recipients who received LET for primary CMV prophylaxis following VGCV intolerance. Patients were matched 1:1 to historical VGCV controls based on age, serostatus group, and time from transplant. The primary outcome was CMV breakthrough within 1 year post‐LET initiation; secondary outcomes included hematologic changes.
Results
A total of 124 lung transplant recipients were included per group (32% CMV mismatch, D+R‐), with LET initiated a median of 9.6 months post‐transplantation. One CMV breakthrough event (0.8%) was observed in the LET group versus four (3.2%) in the VGCV group ( p = .370). The median (interquartile range) white blood cell (WBC) count was 3.1 (2.1–5.6) at LET initiation which increased to 5.1 (3.9–7.2) at the end of follow‐up ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Division of Transplant Pulmonology, Norton Thoracic Institute, Dignity Health, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale, Arizona, USA.
ORCID-Profile: Sydni Martinez, Devika Sindu, Lauren Cherrier, Sofya Tokman, Rajat Walia, Kellie J Goodlet
Zitieren
APA
Martinez, S., Sindu, D., Nailor, M. D., Cherrier, L., Tokman, S., Walia, R., & Goodlet, K. J. (2024). Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14279
Vancouver
Martinez S, Sindu D, Nailor MD, Cherrier L, Tokman S, Walia R, et al. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients. Transplant Infectious Disease. 2024. doi:10.1111/tid.14279
BibTeX
@article{Martinez2024,
author = {Martinez, Sydni and Sindu, Devika and Nailor, Michael D and Cherrier, Lauren and Tokman, Sofya and Walia, Rajat and Goodlet, Kellie J},
title = {Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14279}
}
EUVIMED